

U.S. National Library of Medicine National Center for Biotechnology Information **NLM Citation:** Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Ixekizumab. [Updated 2018 Dec 3]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



# Ixekizumab

Revised: December 3, 2018.

CASRN: 1143503-69-8

## **Drug Levels and Effects**

### Summary of Use during Lactation

No information is available on the clinical use of ixekizumab during breastfeeding. Because ixekizumab is a large protein molecule with a molecular weight of 146,000, absorption by the infant is unlikely after the first few weeks postpartum, and it will probably be destroyed in the infant's gastrointestinal tract. Until more data become available, ixekizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

### **Drug Levels**

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

### **Effects in Breastfed Infants**

Relevant published information was not found as of the revision date.

### **Effects on Lactation and Breastmilk**

Relevant published information was not found as of the revision date.

### **Alternate Drugs to Consider**

(Psoriasis) Adalimumab, Etanercept, Infliximab, Phototherapy, Tretinoin

# **Substance Identification**

### Substance Name

Ixekizumab

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site .

### **CAS Registry Number**

1143503-69-8

#### **Drug Class**

Breast Feeding

Lactation

Antibodies, Monoclonal, Humanized

Dermatologic Agents